Data Presentation: Reata Announces Improvements in Kidney Function with Bardoxolone Methyl Maintained for Two Years in PAH Patients from LARIAT Trial

Reata announced results from the long-term follow up portion of the LARIAT study demonstrating that pulmonary arterial hypertension patients treated with bardoxolone methyl experienced kidney function improvements that were durable for two years and not associated with adverse outcomes.

  • Patients in the placebo-controlled, double blind phase of LARIAT had impaired kidney function upon study entry with an eGFR averaging 75.6 mL/min/1.73 m². Patients who received treatment with bardoxolone methyl (n=71) had significantly increased eGFR compared to placebo (n=30) by 10.6 mL/min/1.73 m² (p<0.0001) after 16 weeks of treatment.
  • After 56 weeks of treatment, patients experienced a significant, mean increase in eGFR of 10.7 mL/min/1.73 m² from baseline (p<0.0001), and after 104 weeks of treatment, patients experienced a significant, mean increase in eGFR of 11.3 mL/min/1.73 m² from baseline (p<0.0001).
  • 88% of patients on bardoxolone methyl who reached week 104 maintained increases in eGFR above baseline after two years of treatment.